12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GDC-0973: Interim Phase Ib data

Interim data from 70 patients with locally advanced or unresectable metastatic melanoma and a BRAF V600 mutation in the dose-escalation Phase Ib BRIM7 trial showed that 2 cohorts evaluating 60 mg oral GDC-0973 plus 720 or 960 mg oral Zelboraf vemurafenib met the protocol-defined criteria for safety and were expanded to include up to 20 BRAF inhibitor-naïve patients who progressed on Zelboraf. There was 1 DLT...

Read the full 317 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >